Two Sigma Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Two Sigma Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,000	Closed	-$370K	–	2496
2014 Q4	$370K	Buy	+2,000	New	+$371K	﹤0.01%	1812
2014 Q3	–	Sell	-11,000	Closed	-$1.72M	–	2759
2014 Q2	$1.72M	Buy	+11,000	New	+$1.74M	0.01%	893
2014 Q1	–	Sell	-2,000	Closed	-$266K	–	2621
2013 Q4	$266K	Hold	2,000	–	–	﹤0.01%	1971
2013 Q3	$232K	Sell	2,000 -1,000	-33%	-$110K	﹤0.01%	1843
2013 Q2	$277K	Buy	+3,000	New	+$289K	﹤0.01%	1775

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Two Sigma Advisers's ALXN Position: Q3 2021 in Review

Two Sigma Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 13,700 shares — an estimated $2.52M sold.

Two Sigma Advisers first reported a position in ALXN in Q2 2013 and held it in 30 quarters. The position peaked at $64.3M in Q3 2016. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Two Sigma Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Two Sigma Advisers sold 13,700 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.52M.
Two Sigma Advisers first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 30 quarters.
Two Sigma Advisers's Alexion Pharmaceuticals position peaked at $64.3M in Q3 2016.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Two Sigma Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.